Trial Outcomes & Findings for Use of a Novel Catheter Lock Solution For Treatment of Hemodialysis Catheter Infections (NCT NCT01483872)

NCT ID: NCT01483872

Last Updated: 2019-09-06

Results Overview

Nine participants signed consent forms, only one randomized. Data was not analyzed.

Recruitment status

TERMINATED

Study phase

PHASE3

Target enrollment

9 participants

Primary outcome timeframe

90 days

Results posted on

2019-09-06

Participant Flow

9 patients signed consent forms. Only one developed an active infection and thus underwent randomization.

Participant milestones

Participant milestones
Measure
NAC/Tigecycline/Heparin Combination Lock Solution
A combination of the above three drugs will form the catheter lock solution that will be instilled into the catheter NAC/Tigecycline/Heparin combination lock solution
Standard Anticoagulant (Heparin or Citrate)
Standard anticoagulant (heparin or citrate) Standard anticoagulant (Heparin or Citrate)
Overall Study
STARTED
0
1
Overall Study
COMPLETED
0
1
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Use of a Novel Catheter Lock Solution For Treatment of Hemodialysis Catheter Infections

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
All Participants
n=9 Participants
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
4 Participants
n=5 Participants
Age, Categorical
>=65 years
5 Participants
n=5 Participants
Sex: Female, Male
Female
2 Participants
n=5 Participants
Sex: Female, Male
Male
7 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
1 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
1 Participants
n=5 Participants
Race (NIH/OMB)
White
5 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
n=5 Participants

PRIMARY outcome

Timeframe: 90 days

Population: Nine participants signed consent forms, only one randomized. Data was not analyzed.

Nine participants signed consent forms, only one randomized. Data was not analyzed.

Outcome measures

Outcome data not reported

Adverse Events

All Participants

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Saima Aslam

UCSD

Phone: 858 657 7463

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place